190 related articles for article (PubMed ID: 37223910)
41. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
[No Abstract] [Full Text] [Related]
42. Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.
Kurimchak AM; Shelton C; Duncan KE; Johnson KJ; Brown J; O'Brien S; Gabbasov R; Fink LS; Li Y; Lounsbury N; Abou-Gharbia M; Childers WE; Connolly DC; Chernoff J; Peterson JR; Duncan JS
Cell Rep; 2016 Aug; 16(5):1273-1286. PubMed ID: 27452461
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.
Ibrahim AF; Weirauch U; Thomas M; Grünweller A; Hartmann RK; Aigner A
Cancer Res; 2011 Aug; 71(15):5214-24. PubMed ID: 21690566
[TBL] [Abstract][Full Text] [Related]
44. The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib.
Villaume MT; Arrate MP; Ramsey HE; Sunthankar KI; Jenkins MT; Moyo TK; Smith BN; Fischer MA; Childress MA; Gorska AE; Ferrell PB; Savona MR
Exp Hematol; 2021 May; 97():57-65.e5. PubMed ID: 33617893
[TBL] [Abstract][Full Text] [Related]
45. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.
Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z
Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665
[TBL] [Abstract][Full Text] [Related]
46. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.
Wong C; Laddha SV; Tang L; Vosburgh E; Levine AJ; Normant E; Sandy P; Harris CR; Chan CS; Xu EY
Cell Death Dis; 2014 Oct; 5(10):e1450. PubMed ID: 25299775
[TBL] [Abstract][Full Text] [Related]
47. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
Frankel AE; Lilly M; Kreitman R; Hogge D; Beran M; Freedman MH; Emanuel PD; McLain C; Hall P; Tagge E; Berger M; Eaves C
Blood; 1998 Dec; 92(11):4279-86. PubMed ID: 9834234
[TBL] [Abstract][Full Text] [Related]
48. BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.
Hogg SJ; Vervoort SJ; Deswal S; Ott CJ; Li J; Cluse LA; Beavis PA; Darcy PK; Martin BP; Spencer A; Traunbauer AK; Sadovnik I; Bauer K; Valent P; Bradner JE; Zuber J; Shortt J; Johnstone RW
Cell Rep; 2017 Feb; 18(9):2162-2174. PubMed ID: 28249162
[TBL] [Abstract][Full Text] [Related]
49. Vitamin C Sensitizes Melanoma to BET Inhibitors.
Mustafi S; Camarena V; Volmar CH; Huff TC; Sant DW; Brothers SP; Liu ZJ; Wahlestedt C; Wang G
Cancer Res; 2018 Jan; 78(2):572-583. PubMed ID: 29180474
[TBL] [Abstract][Full Text] [Related]
50. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
[TBL] [Abstract][Full Text] [Related]
51. Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies.
Lasorsa E; Smonksey M; Kirk JS; Rosario S; Hernandez-Ilizaliturri FJ; Ellis L
Cell Death Dis; 2015 Dec; 6(12):e2014. PubMed ID: 26658189
[TBL] [Abstract][Full Text] [Related]
52. Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related.
Lilly M; Le T; Holland P; Hendrickson SL
Oncogene; 1992 Apr; 7(4):727-32. PubMed ID: 1314369
[TBL] [Abstract][Full Text] [Related]
53. Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.
Kloos A; Mintzas K; Winckler L; Gabdoulline R; Alwie Y; Jyotsana N; Kattre N; Schottmann R; Scherr M; Gupta C; Adams FF; Schwarzer A; Heckl D; Schambach A; Imren S; Humphries RK; Ganser A; Thol F; Heuser M
Leukemia; 2020 Nov; 34(11):2951-2963. PubMed ID: 32576961
[TBL] [Abstract][Full Text] [Related]
54. BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
Gusyatiner O; Bady P; Pham MDT; Lei Y; Park J; Daniel RT; Delorenzi M; Hegi ME
Neuro Oncol; 2021 Oct; 23(10):1680-1692. PubMed ID: 33987681
[TBL] [Abstract][Full Text] [Related]
55. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
[TBL] [Abstract][Full Text] [Related]
56. Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance.
Huang SM; Wang A; Greco R; Li Z; Barberis C; Tabart M; Patel V; Schio L; Hurley R; Chen B; Cheng H; Lengauer C; Pollard J; Watters J; Garcia-Echeverria C; Wiederschain D; Adrian F; Zhang J
Oncotarget; 2014 May; 5(10):3362-74. PubMed ID: 24830942
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
Puente-Moncada N; Costales P; Antolín I; Núñez LE; Oro P; Hermosilla MA; Pérez-Escuredo J; Ríos-Lombardía N; Sanchez-Sanchez AM; Luño E; Rodríguez C; Martín V; Morís F
Mol Cancer Ther; 2018 Mar; 17(3):614-624. PubMed ID: 29339551
[TBL] [Abstract][Full Text] [Related]
58. Induction of MNK Kinase-dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors.
Pham TND; Kumar K; DeCant BT; Shang M; Munshi SZ; Matsangou M; Ebine K; Munshi HG
Mol Cancer Ther; 2019 Feb; 18(2):235-244. PubMed ID: 30446586
[TBL] [Abstract][Full Text] [Related]
59. Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.
Hunter AM; Newman H; Dezern AE; Steensma DP; Niyongere S; Roboz GJ; Mo Q; Chan O; Gerds A; Sallman DA; Dominguez-Viqueira W; Letson C; Balasis ME; Ball M; Kruer T; Zhang H; Lancet JE; List AF; Sekeres MA; Komrokji RS; Padron E
Clin Cancer Res; 2021 Nov; 27(22):6095-6105. PubMed ID: 34253584
[TBL] [Abstract][Full Text] [Related]
60. Disruption of CTCF Boundary at HOXA Locus Promote BET Inhibitors' Therapeutic Sensitivity in Acute Myeloid Leukemia.
Zha J; Lai Q; Deng M; Shi P; Zhao H; Chen Q; Wu H; Xu B
Stem Cell Rev Rep; 2020 Dec; 16(6):1280-1291. PubMed ID: 33057942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
